Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd

₹ 439 -0.91%
04 Oct - close price
About

Incorporated in 2008, Mumbai-based Sudarshan Pharma Industries Limited (SPIL) has a contract manufacturing facility for generic formulations. It is also engaged in import & export activities, and supply of specialty chemicals, API, and Intermediates[1]

Key Points

Business Area
A) Specialty Chemicals, Intermediates & API[1] Co. is involved in Manufacturing, Imports of specialty chemicals & exports, as well as outsourcing & Supply of Specialty chemicals, bulk drugs, and API for domestic and international clients in Pharma, agrochemicals, Paints, resins & various industry.

  • Market Cap 1,056 Cr.
  • Current Price 439
  • High / Low 453 / 58.2
  • Stock P/E 93.0
  • Book Value 46.4
  • Dividend Yield 0.00 %
  • ROCE 13.6 %
  • ROE 10.7 %
  • Face Value 10.0

Pros

  • Company has delivered good profit growth of 37.0% CAGR over last 5 years

Cons

  • Stock is trading at 9.46 times its book value
  • Company has a low return on equity of 12.1% over last 3 years.
  • Debtor days have increased from 78.7 to 96.5 days.
  • Working capital days have increased from 87.8 days to 139 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Trading Industry: Trading

Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Mar 2023 Sep 2023 Mar 2024
149 266 232 234
144 258 223 220
Operating Profit 5 8 8 14
OPM % 4% 3% 4% 6%
1 1 2 1
Interest 2 3 3 6
Depreciation 0 0 1 1
Profit before tax 4 5 7 9
Tax % 25% 26% 25% 24%
3 4 5 6
EPS in Rs 3.15 1.47 2.03 2.68
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
55 88 139 148 193 357 461 466
55 87 135 143 186 346 446 443
Operating Profit 1 1 4 5 7 11 15 23
OPM % 1% 1% 3% 3% 4% 3% 3% 5%
0 2 1 0 0 0 1 3
Interest 0 1 2 3 3 3 5 9
Depreciation 0 0 0 0 1 1 1 1
Profit before tax 0 1 3 2 4 7 10 15
Tax % 40% 24% 28% 26% 25% 26% 26% 25%
0 1 2 1 3 5 7 11
EPS in Rs 0.74 1.57 2.46 1.34 2.80 5.39 2.93 4.72
Dividend Payout % 0% 0% 0% 0% 0% 0% 10% 0%
Compounded Sales Growth
10 Years: %
5 Years: 27%
3 Years: 34%
TTM: 1%
Compounded Profit Growth
10 Years: %
5 Years: 37%
3 Years: 62%
TTM: 57%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 429%
Return on Equity
10 Years: %
5 Years: 12%
3 Years: 12%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 2 5 10 10 10 10 24 24
Reserves 1 4 9 10 13 20 77 88
6 10 14 21 30 31 34 107
11 12 17 18 47 77 97 66
Total Liabilities 20 31 50 58 99 138 232 285
0 0 2 6 6 6 20 21
CWIP 0 0 2 0 0 1 0 2
Investments 0 0 0 0 0 0 12 17
20 31 47 53 93 130 200 245
Total Assets 20 31 50 58 99 138 232 285

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-2 -0 -1 1 3 -4 -29 8
-0 -0 -4 -3 -1 -2 -26 -7
2 -1 8 -0 -2 4 66 -12
Net Cash Flow 0 -1 3 -2 -0 -1 11 -12

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 92 71 68 66 114 75 64 96
Inventory Days 23 28 29 46 49 51 63 73
Days Payable 75 49 45 40 90 80 78 49
Cash Conversion Cycle 40 51 52 72 73 46 50 120
Working Capital Days 42 52 53 69 75 53 71 139
ROCE % 16% 20% 12% 15% 19% 15% 14%

Shareholding Pattern

Numbers in percentages

38 Recently
Mar 2023Sep 2023Mar 2024
57.39% 57.39% 57.39%
3.58% 1.40% 1.40%
39.02% 41.20% 41.21%
No. of Shareholders 1,244983913

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents